Bukwang Withdraws Market Approval Request for Clevudine

Bukwang Pharmaceutical announced on March 7th that it has made an autonomous withdrawal of its application submitted for a domestic market approval of anti-hepatitis B agent clevudine to the Korea Food and Drug Administration (KFDA).

According to the company, the decision to withdraw clevudine's market approval is based on a lack of certain application materials that are deemed not as adequa...